Immune markers in fibromyalgia: Comparison with major depressed patients and normal volunteers

Journal of Affective Disorders

Volumn 48, Issue 1, 1998, Pages 75-82

  Bonaccorso, Stefania ^a   Lin, Ai Hua ^a   Verkerk, Robert ^c   Van Hunsel, Fran ^a   Libbrecht, Isabelle ^a   Scharpé, Simon ^c   DeClerck, Luc ^c   Biondi, Massimo ^b   Janca, Aleksander ^d   Maes, Michael ^a  

^a Clinical Research Center for Mental Health of Antwerp   (Belgium)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Antidepressants; Cellular immunity; Depression; Fibromylagia; Neopterin; Selective serotonin reuptake inhibitors

Indexed keywords

ANTIDEPRESSANT AGENT; BIOPTERIN; CREATININE; CYTOKINE; NEOPTERIN; PLACEBO; PSEUDOURIDINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; URIC ACID;

AFFECTIVE NEUROSIS; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; FIBROMYALGIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MULTICENTER STUDY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RHEUMATIC DISEASE; TREATMENT OUTCOME; URINARY EXCRETION;

EID: 0031888893     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(97)00144-4     Document Type: Article

References (46)

1. American Psychiatric Association, 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. American Psychiatric Association, Washington, DC.
2. Anderson D.N., Abou-Saleh M.T., Collins J., Hughes K., Cattell R.J., Hamon C.G.B., Blair J.A., Dewey M.E. Pterin metabolism in depression: an extension of the amine hypothesis and possible marker of response to ECT. Psychol. Med. 22:1992;863-869.
3. Bridges A.J. Fibromyalgia, antinuclear antibodies and clinical features of connective tissue disease (letter). Clin. Exp. Rheumatol. 11:1993;696-697.
4. Bridges A.J., Anderson J.D., Burns D.E., Kemple K., Kaplan J.D., Lorden T. Autoantibodies in patients with silicone implants. Curr. Top. Microbiol. Immunol. 210:1996;277-282.
5. Clauw D.J. The pathogenesis of chronic pain and fatigue syndromes, with special reference to fibromyalgia. Med. Hypoth. 44:1995;369-378.
6. Duch D.S., Woolf J.H., Nichol C.A., Jonathan R.D., Garbutt J.C. Urinary excretion of biopterin and neopterin in psychiatry disorders. Psychiatr. Res. 11:1983;83-89.
7. Dunbar P.R., Hill J., Neale T.J., Mellsop G.W. Neopterin measurement provides evidence of altered cell-mediated immunity in patients with depression, but not with schizophrenia. Psychol. Med. 22:1992;1051-1057.
8. Giovannoni G., Lai M., Kidd D., Thorpe J.W., Miller D.H., Thompson A.J., Kleir G., Feldmann M., Thompson E.J. Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis. Brain. 120:1997;1-13.
9. Goldenberg D.N. Management of fibromyalgia syndrome. Rheum. Dis. Clin. North Am. 15:1989;499-512.
10. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry. 23:1960;56-61.
11. Hawley D.J., Wolfe F. Depression is not more common in rheumatoid arthritis: a 10-year longitudinal study of 6153 patients with rheumatic disease. J. Rheumatol. 20:1993;2025-2031.
12. Hench P.K., Mitler M.M. Fibromyalgia: 2. Management guidelines and research findings. Postgrad. Med. 80:1986;57-69.
13. Hernanz W., Valenzuela A., Quijada J., Garcia A., De La Iglesia J.L., Gutierrez A., Povedano J., Moreno I., Sanchez B. Lymphocyte subpopulations in patients with primary fibromyalgia. J. Rheumatol. 21:1994;2122-2124.
14. Heyes M.P., Quearry B.J. Increased L-tryptophan, 5-hydroxyindoleacetic acid, 3-hydroxykynurenine and quinolonic acid concentrations in cerebral cortex following systemic endotoxin administration. Adv. Exp. Med. Biol. 294:1991;559-562.
15. Hu B., Hissong B.D., Carlin J.M. Interleukin-1 enhances indoleamine 2,3-dioxygenase activity by increasing specific mRNA expression in human mononuclear phagocytes. J. Interferon Cyt. Res. 15:1995;617-624.
16. Hudson J.I., Hudson M.S., Pliner L.F., Goldenberg D.L., Pope H.G. Jr. Fibromyalgia and major affective disorder: a controlled phenomenology and family history study. Am. J. Psychiatry. 142:1985;441-446.
17. Jacobsen S., Jensen K.E., Thomsen C., Danneskiold-Samsoe B., Henriksen O. 31-P magnetic resonance spectroscopy of skeletal muscle in patients with fibromyalgia. J. Rheumatol. 19:1992;1600-1603.
18. Jacobsen S., Gam A., Egsmose C., Olsen M., Danneskiold-Samsoe B., Finn Jensen G. Bone mass and turnover in fibromyalgia. J. Rheumatol. 20:1993;856-858.
19. Joyce P.R., Hawes C.R., Mulder R.T., Sellman J.D., Wilson D.A., Boswell D.R. Elevated levels of acute phase plasma proteins in major depression. Biol. Psychiatry. 32:1992;1035-1041.
20. Klein R., Bansch M., Berg P.A. Clinical relevance of antibodies against serotonin and gangliosides in patients with primary fibromyalgia syndrome. Psychoneuroendocrinology. 17:1992;593-598.
21. Klein R., Berg P.A. A comparative study on antibodies to nucleoli and 5-hydroxytryptamine in patients with fibromyalgia syndrome and tryptophan-induced eosinophilia-myalgia syndrome. Clin. Invest. 72:1994;541-549.
22. Krag N.J., Norregaard J., Larsen J.K., Danneskiold-Samsoe B. A blinded controlled evaluation of anxiety and depressive symptoms in patients with fibromyalgia, as measured by standardized psychometric interview scales. Acta Psychiatr. Scand. 89:1994;370-375.
23. Lijnen P., Hespel P., Vanden Eynde E., Amery A. Urinary excretion of electrolytes during prolonged physical activity in normal man. Eur. J. Appl. Physiol. 53:1985;317-321.
24. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 19:1995;11-38.
25. Maes M., Scharpe S., Cooremans W., VanGrootel L., Uyttenbrouck W., Minner B., Suy E., Cosyns P. Higher α1-antitrypsine, haptoglobin, and ceruloplasmin, and lower retinol binding protein plasma levels in major depressed subjects. J. Affect. Disord. 24:1992;183-192.
26. Maes M., Meltzer H.Y., Stevens W., Cosyns P., Blockx P. Multiple reciprocal relationships between in vivo cellular immunity and hypothalamic-pituitary-adrenal axis in depression. Psychol. Med. 24:1994;167-177.
27. Maes M., Scharpé S., Meltzer H.Y., Okayli G., Bosmans E., D'Hondt P., Vanden Bossche B., Cosyns P. Increased neopterin and interferon-g secretion and lower availability of L-tryptophan in major depression: further evidence for activation of cell-mediated immunity. Psychiatr. Res. 54:1994;143-160.
28. Maes M., Bosmans E., Meltzer H.Y. Immunoendocrine aspects of major depression: relationships between plasma interleukin-6 and soluble interleukin-2 receptor, prolactin and cortisol. Eur. Arch. Psychiatr. Clin. Neurosci. 245:1995;172-178.
29. Maes M., Smith R., Scharpe S. The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinology. 20:1995;111-116.
30. Maes, M., Bosmans, E., De Jongh, R., Kenis, G., Vandoolaeghe, E., Neels, H., 1997. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine, in press.
31. Motyl T., Traczyk Z., Holska W., Daniewska-Michalska D., Ciesluk S., Kukulska W., Kaluzny Z., Podgurniak M. Comparison of urinary neopterin and pseudouridine in patients with malignant proliferative diseases. Eur. J. Clin. Chem. Clin. Biochem. 31:1993;205-209.
32. Nichol C.A., Smith G.K., Duch D.S. Biosynthesis and metabolism of tetrahydrobiopterin and molybdopterin. Annu. Rev. Biochem. 54:1985;729-764.
33. Puttini P.S., Caruso I. Primary fibromyalgia syndrome and 5-hydroxy-L-tryptophan: a 90-day open study. J. Int. Med. Res. 20:1992;182-189.
34. Russell I.J. Neurohormonal aspects of fibromyalgia syndrome. Rheum. Dis. Clin. North Am. 15:1989;149-165.
35. Russell I.J., Michalek J.E., Vipraio G.A., Fletcher E.M., Javors M.A., Bowden C.A. Platelet 3-H imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. J. Rheumatol. 19:1991;104-109.
36. Saccomani L., Vigliarolo M.A., Sbolgi P., Ruffa G., Doria Lamba L. Sindrome fibromialgica giovanile: due casi clinici. Ped. Med. Chir. (Med. Surg. Ped.). 15:1993;99-101.
37. Saito K., Markey S.P., Heyes P. Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse. Neuroscience. 51:1992;25-39.
38. Seidel A., Arolt V., Hunstiger M., Rink L., Behnisch A., Kirchner H. Increased CD56+ natural killer cells and related cytokines in major depression. Clin. Immunol. Immunopathol. 78:1996;83-85.
39. Sluzewska A., Rybakowski J., Bosmans E., Sobieska M., Berghmans R., Maes M., Wiktorwicz K. Indicators of immune activation in major depression. Psychiatr. Res. 64:1996;161-167.
40. Smith R.S. The macrophage theory of depression. Med. Hypoth. 35:1991;298-306.
41. Song C., Dinan T., Leonard B.E. Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls. J. Affect. Disord. 30:1994;283-288.
42. Takikawa, O., Yoshida, R., Yasui, H., Hayaishi, O., 1984. The relationship between plasma kynurenine and indoleamine 2,3-dioxygenase activity in the extrahepatic tissues. In: Schlossberger, H.G., Kochen, W., Linzen, B., Steinhart, H. (Eds.), Progress in Tryptophan and Serotonin Research. Walter de Gruyter, Berlin-New York, pp. 517-520.
43. Van Acker K.J., Eyskens F.J., Verkerk R.M., Scharpé S. Urinary excretion of purine and pyrimidine metabolites in the neonate. Pediatr. Res. 34:1993;762-766.
44. Wolfe F., Smythe H.A., Yunus M.B., Bennett R.M., Bombardier C., Goldenberg D.L., Tugwell P., Campbell S.M., Abeles M., Clark P.et al. The American College of Rheumatology 1990: Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthr. Rheumatol. 33:1990;160-172.
45. Yunus M.B., Dailey J.W., Aldag J.C., Masi A.T., Jobe P.C. Plasma tryptophan and other amino acids in primary fibromyalgia: a controlled study. J. Rheumatol. 19:1992;90-94.
46. Yunus M.B., Hussey F.X., Aldag J.C. Antinuclear antibodies and connective tissue disease features in fibromyalgia syndrome: a controlled study. J. Rheumatol. 20:1993;1557-1560.